• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Acute Myocardial Infarction in Severe Mental Illness: Prevalence, Clinical Outcomes, and Process of Care in U.S. Hospitalizations
ConclusionSchizophrenia and ONOP are the only SMI subtypes associated with adverse clinical outcomes after AMI. However, all patients with SMI were less likely to receive invasive management for AMI, with female gender and schizophrenia diagnosis being the strongest predictors of conservative management. A multidisciplinary approach between psychiatrists and cardiologists could improve the outcomes of this high-risk population.RésuméContexteLe trouble mental grave (TMG) est associé à une augmentation de la mortalité cardiovasculaire. Nous avons étudié la prévalence des patients atteints d’un TMG qui avaient subi ...
Source: Canadian Journal of Cardiology - July 8, 2019 Category: Cardiology Source Type: research

Acute Myocardial Infarction in Severe Mental Health Illness: prevalence, clinical outcomes and process of care in United States hospitalizations.
ConclusionSchizophrenia and ‘other non-organic psychoses’ are the only SMI subtypes associated with adverse clinical outcomes after AMI. However, all patients with SMI were less likely to receive invasive management for AMI, with women and schizophrenia diagnosis being the strongest predictors of conservative management. A multidisciplinary approach between psychiatrists and cardiologists could improve outcomes of this high-risk population.
Source: Canadian Journal of Cardiology - May 3, 2019 Category: Cardiology Source Type: research

Psychosis Polyrisk Score (PPS) for the Detection of Individuals At-Risk and the Prediction of Their Outcomes
Conclusions The combination of risk/protective factors encompassing genetic (PRS) and non-genetic information (PPS) holds promise for overcoming the epidemiological weakness of the CHR-P paradigm. The PPS conceptually and empirically developed here will facilitate future research in this field and hopefully advance our ability to detect individuals at-risk for psychosis and forecast their clinical outcomes. Ethics Statement This study was supported by the King's College London Confidence in Concept award from the Medical Research Council (MRC) (MC_PC_16048) to PF-P. This study also represents independent researc...
Source: Frontiers in Psychiatry - April 16, 2019 Category: Psychiatry Source Type: research

Functional MRI of Letter Cancellation Task Performance in Older Adults
Conclusion The present work is the first to identify neural correlates of the LCT using fMRI and tablet technology in a healthy aging population. Across all ages, the activation was found to be bilateral, including in the cerebellum, superior temporal lobe, precentral gyrus, frontal gyrus, and various occipital and parietal areas. With increasing age, performance generally decreased and brain activity was reduced in the supplementary motor area, middle and inferior frontal gyrus, middle occipital gyrus, putamen and cerebellum. Better LCT performance was correlated with increased activity in the middle frontal gyrus, and r...
Source: Frontiers in Human Neuroscience - April 15, 2019 Category: Neuroscience Source Type: research

Atorvastatin in the treatment of lithium-induced nephrogenic diabetes insipidus: the protocol of a randomized controlled trial
Lithium is the gold-standard treatment for bipolar disorder, is highly effective in major depressive disorder, and is being investigated for therapeutic benefits in dementia, stroke, and even cancer. Approximately 350,000 Canadians use lithium and more could benefit. Despite this, clinicians are avoiding lithium, largely due to fear of renal toxicity, including irreversible chronic kidney disease (CKD). Nephrogenic Diabetes Insipidus (NDI) occurs in 20% of lithium users and independently predicts a 2-3 times increased risk of CKD.
Source: The American Journal of Geriatric Psychiatry - February 28, 2019 Category: Geriatrics Authors: Jocelyn Fotso Soh, Gabriela Torres-Platas, Serge Beaulieu, Outi Mantere, Robert Platt, Istvan Mucsi, Sybille Saury, Suzane Renaud, Andrea Levinson, Ana Andreazza, Benoit Mulsant, Daniel Mueller, Ayal Schaffer, Annemiek Dols, Nancy Low, Pablo Cervantes, Na Tags: Poster Number: EI - 48 Source Type: research

rTMS Effects in Patients with Co-Morbid Somatic Pain and Depressive Mood Disorders
Repetitive Transcranial Magnetic Stimulation (rTMS) is a non-invasive neuromodulation treatment that involves the induction of electrical currents in a targeted region of the brain with the ability to impact various functional processes (Chervyakov  et al., 2015). rTMS has shown to provide clinical improvement among a variety of neurological and psychiatric disorders and has been FDA-approved for treatment resistant depression (TRD). rTMS continues to undergo trials for other treatment indications including post-traumatic stress disorder (PT SD), generalized anxiety disorder (GAD), bipolar depression, schizophrenia, stro...
Source: Journal of Affective Disorders - August 18, 2018 Category: Neurology Authors: Angela L. Phillips, Robert L. Burr, David L. Dunner Tags: Research paper Source Type: research

Atrial Fibrillation and Injected Aripiprazole: A Case Report
Conclusion In summary, although it is not possible to exclude confounding factors, the timing and dose-dependent effect of aripiprazole administration in our patient suggests an association between an initial intramuscular injection of long-acting aripiprazole and new onset of AF. This observation calls for clinical vigilance, not only in patients with additional risk factors for stroke but also in younger patients who might have predisposing factors for arrhythmias. References CPS (Canadian Pharmacists Association). Available at: http://www.e-therapeutics.ca. Accessed January 1, 2017. Polcwiartek C, Sneider B, Graff C,...
Source: Innovations in Clinical Neuroscience - May 1, 2018 Category: Neuroscience Authors: ICNS Online Editor Tags: Case Report Current Issue adverse effects aripiprazole atrial fibrillation schizoaffective disorder Source Type: research

CNS Summit 2017 Abstracts of Poster Presentations
Conclusion: This novel technology discriminates and quantifies subtle differences in behavior and neurological impairments in subjects afflicted with neurological injury/disease. KINARM assessments can be incorporated into multi-center trials (e.g., monitoring stroke motor recovery: NCT02928393). Further studies will determine if KINARM Labs can demonstrate a clinical effect with fewer subjects over a shorter trial period. Disclosures/funding: Dr. Stephen Scott is the inventor of KINARM and CSO of BKIN Technologies.   Multiplexed mass spectrometry assay identifies neurodegeneration biomarkers in CSF Presenter: Chelsky...
Source: Innovations in Clinical Neuroscience - November 1, 2017 Category: Neuroscience Authors: ICNS Online Editor Tags: Assessment Tools biomarkers Cognition Current Issue Drug Development General Genetics Medical Issues Neurology Patient Assessment Psychopharmacology Scales Special Issues Supplements Trial Methodology clinical trials CNS Su Source Type: research